Focus: RheoSense is a newly founded (2024) biotechnology company specializing in viscometer technology for neurology applications, based in San Ramon, CA. The company is in very early stage with minimal public footprint and no disclosed revenue.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
RheoSense is a speculative early-stage entry with potential learning upside but substantial risk; suitable only for risk-tolerant candidates seeking startup equity upside and neurology domain expertise.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for RheoSense
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from RheoSense's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles